CRISPR Therapeutics AG announced on October 19, 2026, that Andrew J. Silver has been appointed as the company's Chief Financial Officer, effective immediately. Mr. Silver, who previously served as Senior Vice President of Finance, will also assume the roles of principal financial officer and principal accounting officer. This appointment follows the resignation of Raju Prasad, Ph.D., who informed the company of his intention to pursue external opportunities. Dr. Prasad is expected to remain employed with CRISPR Inc. until a date on or before November 30, 2026.
Mr. Silver has been with CRISPR Therapeutics since October 2018, holding various roles with increasing responsibility, including strategic finance, treasury, financial planning and analysis, and accounting. Prior to joining the company, he spent more than 10 years at Ernst & Young LLP, most recently as a Senior Manager in Assurance Services. He holds a Master of Science in accounting from the University of Connecticut School of Business and a Bachelor of Science in finance, accounting, and history from Boston College.
Under the terms of a new Employment Agreement dated October 19, 2026, Mr. Silver will receive an annual base salary of $515,000. He is eligible for an annual bonus with a target of 45% of his base salary, with the 2026 bonus pro-rated based on his promotion date. Additionally, he will receive a one-time grant of 25,000 restricted stock units, which will vest in full on the second anniversary of the grant date, subject to continued service. The agreement includes provisions for a six-month notice period in the event of termination without cause or resignation for good reason, with specific acceleration terms applicable if a Change in Control occurs within 12 months of such termination.
